Welcome back to Epsicom Pharmaceutical & Medical Devices Analysis. Todays post concerns the cancer drug Avastin, the first VEGF inhibitor, and its position in the oncology market relative to its competitors.
The Threats To Avastin report was researched and written by the 4D Pharma team. The report’s editor is Espicom’s senior pharmaceutical analyst, Sue Viney.
As an angiogenesis inhibitor, Avastin is set to become the most successful cancer treatment to date and one of the leading drugs with sales likely to exceed US$9 billion by 2015.
Since its launch in 2004, Avastin has achieved strong growth culminating in sales of US$5,731 million (SFr 6.2 billion) in 2009. Not only is Avastin now Roche’s top-selling oncology product, ahead of both MabThera/Rituxan (rituximab) and Herceptin (trastuzumab), but its sales exceed those of every other cancer product on the market.
In 2009, solid growth was seen across all markets, driven by continued uptake in colorectal cancer (CRC), breast cancer (BC) and non-small cell lung cancer (NSCLC). In the US, metastatic BC was the main growth driver, helped by launches for the new indications of glioblastoma and renal cell carcinoma (RCC). Strong growth was seen in the EU in all indications. In the Japanese market, Avastin sales growth was particularly strong with continued substantial uptake in CRC, enhanced by its recent approval for NSCLC.
While its first-to-market status and Roche’s experience in the oncology sector have provided a sound basis for growth, a number of related angiogenesis products have been launched and many more are on the horizon. What threat do they present to Avastin’s status and when will their impact be felt?
If you would like to read more on Avastin the first angiogenesis inhibitor in the oncology market, to see what is included in the report, or to purchase this detailed analysis, please follow our link:
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment